The scopolamine market is expected to grow at a CAGR of around 4.5% during the forecast period. Scopolamine is also known as Hyoscine that is majorly used to treat motion sickness & nausea and vomiting. It is an alkaloid drug that is extracted from the henbane plant. It is also used as a sedative and can be used along with the morphine to relieve pain. The drug requires a prescription and is not available as an over the counter drug.

Rise in the number of people suffering from stress and anxiety disorder is a major factor for the growth of the scopolamine drug market. Moreover, significant research in the field of Alzheimer's disease treatment is also undergoing related scopolamine which can provide a significant opportunity to the drug if some positive results outcomes witnessed in the near future. 

However, misuse of the drug for the illegal activities is one of the major challenge to the market as the government may strict the regulations related to the distribution of the drug. When scopolamine is mixed in the beverage of a person, it can cause a range of acute psychoses including hallucinations, disorientation, and paranoia. As an estimate, around 50,000 cases of poisoning of scopolamine are registered every year in the US and Colombia each. Moreover, the presence of alternative globally is a restraining factor for the market. Ondansetron, Promethazine, Prochlorperazine are some of the alternative drugs available in the market for the treatment of nausea and vomiting.

Market Segmentation

The global scopolamine market is segmented based on type and dosage type. By type, the market is bifurcated into scopolamine butyl bromide and scopolamine base. Scopolamine butyl bromide is sold under the brand name Buscopan, which is majorly used to treat abdominal pain, esophageal spasms, renal colic, and bladder spasms. Scopolamine base is used to treat motion sickness & nausea and vomiting. Scopolamine base is expected to have a major market share during the forecast period. By dosage type, the market is segmented into oral, injection, and patches. Scopolamine patches have been widely adopted to treat nausea and vomiting due to motion sickness or as anesthesia during surgery. The cost of 4 films of 1 mg is around $50 in the US which is generally used for three days. 

Global Scopolamine Market Share by Dosage Type, 2019 (%)

Regional Outlook

On the basis of geography, the global scopolamine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). During the forecast period, North America is expected to hold a major market share. The US is expected to hold the major market share during the forecast period. The high cost of drugs, frequent traveling of people through airways for small distances, well-developed online supply chains are some of the major factors for the significant market share of the region. 

Europe is also expected to hold a considerable market share during the forecast period. Germany, UK, France are some of the major countries contributing to the market. Asia-Pacific is expected to show a lucrative growth rate during the forecast period. It is due to the increasing air travel in countries such as China, India, Indonesia, and Vietnam. Moreover, increasing awareness of motion sickness, increasing surgeries (domestic as well as medical tourism) in these countries is also one of the major factors contributing to the growth of the market. 

Global Scopolamine Market Growth, by Region 2020-2026

Market Players Outlook

Novartis AG is one of the major players in the market and the sales of the drug under the registered trademark of Transderm Scop. Some other players active in the market include Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Baxter International Inc., Myungmoon Pharm Co. Ltd., Alchem International Pvt. Ltd., Caleb Pharmaceuticals, Inc., Phytex Australia, Fine Chemicals Corp., Perrigo Company plc and others. The market players are adopting growth strategies including mergers & acquisitions, product launches, and partnerships & collaborations to gain a competitive edge in the market. For instance, in July 2017, Perrigo Co. plc along with Aveva Drug Delivery Systems launched generic Transderm Scop (scopolamine, 1.5 mg) patches. It can be used to prevent nausea and vomiting that are associated with motion sickness. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Scopolamine market. 
• Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.